Perran Fulden Yumuk

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu et al. · Journal of Clinical Oncology · 2021 · 253 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples.

Perran Fulden Yumuk, Taflan Salepçi, Mehmet Aliustaoğlu et al. · PubMed · 2006 · 98 citations · Full text

Medicine, Oncology, Pathology +11

Extrapulmonary Small Cell Carcinoma: Multimodality Treatment Results

Meriç Şengöz, Ufuk Abacıoğlu, Taflan Salepçi et al. · Tumori Journal · 2003 · 70 citations · Full text

Medicine, Oncology, Surgery +12

Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy

Hasan Fevzi Batırel, Muzaffer Metintaş, Hale Başak Çağlar et al. · Journal of Thoracic and Cardiovascular Surgery · 2015 · 68 citations · Full text

Medicine, Oncology, Surgery +12